Form 4 for ANIX Anixa Biosciences Inc
Accepted 2022-09-30 00:00:00 ET · period of report 2022-09-29 · accession 0001493152-22-027222 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-09-30 | 2022-09-29 | ANIX | Titterton Lewis H jr | Dir | M - OptEx | $2.58 | +40.0K | 774.1K | +5% | +$103.2K |
| D | 2022-09-30 | 2022-09-29 | ANIX | Titterton Lewis H jr | Dir | M - OptEx | $0.00 | -40.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-09-29 | M | A | 40,000 | $2.58 | 774,070 | D | — | — | |
| 2 | Derivative | Employee Stock Option | 2022-09-29 | M | D | 40,000 | $0.00 | 0 | D | $2.58 · 2013-02-15 to 2023-02-15 | 40,000 Common Stock | (F1) Right-To-Buy, pursuant to a stock option grant dated February 15, 2013. |